DOM-VENLAFAXINE XR CAPSULE (EXTENDED RELEASE)

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE)

제공처:

DOMINION PHARMACAL

ATC 코드:

N06AX16

INN (International Name):

VENLAFAXINE

복용량:

75MG

약제 형태:

CAPSULE (EXTENDED RELEASE)

구성:

VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 75MG

관리 경로:

ORAL

패키지 단위:

500

처방전 유형:

Prescription

치료 영역:

SELECTIVE SEROTONIN AND NOREPINEPHRINE-REUPTAKE INHIBITORS

제품 요약:

Active ingredient group (AIG) number: 0131294001; AHFS:

승인 상태:

APPROVED

승인 날짜:

2013-05-17

제품 특성 요약

PRODUCT MONOGRAPH
PR
DOM-VENLAFAXINE XR
VENLAFAXINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULES
37.5 MG, 75 MG AND 150 MG VENLAFAXINE, AS VENLAFAXINE HYDROCHLORIDE
Antidepressant
DOMINION PHARMACAL
6111 Royalmount Ave, Suite 100
Montréal, Québec
H4P 2T4
DATE OF REVISION:
February 28, 2013
Submission Control No: 116569, 151422, 162398
_ _
_Dom-VENLAFAXINE XR Product Monograph _
_Page 2 of 54 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................15
DRUG INTERACTIONS
..................................................................................................23
DOSAGE AND ADMINISTRATION
..............................................................................30
OVERDOSAGE
................................................................................................................33
ACTION AND CLINICAL PHARMACOLOGY
............................................................34
STORAGE AND STABILITY
..........................................................................................37
SPECIAL HANDLING INSTRUCTIONS
.......................................................................37
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................38
PART II: SCIENTIFIC INFORMATION
...............................................................................39
PHARMACEUTICAL INFORMATION
..........................................................................39
CLINI